01 Technological Innovation in Pathogen Reduction Systems Technological innovation in pathogen reduction systems is transforming the global blood preparation industry by significantly enhancing the safety and efficacy of blood products. These cutting-edge systems work by inactivating a wide range of pathogens including viruses, bacteria, and parasites, thereby reducing the risk of transfusion-transmitted infections and improving patient outcomes. For instance, in October 2024, Cerus secured a $32.1 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to further develop the INTERCEPT Blood System for red blood cells. This system uses amustaline, a small molecule that intercalates and crosslinks nucleic acids, effectively preventing pathogen replication. As regulatory approvals increase and healthcare providers prioritize safer transfusion methods, the adoption of such innovative pathogen reduction technologies is expected to accelerate, driving substantial growth in the market for blood preparation.
01 Increasing Number of Surgical Procedures and Trauma Cases Globally The elevating number of surgical procedures and trauma cases worldwide is a significant driver for the market for blood preparation. Continuous advancements in medical technology, coupled with expanding healthcare infrastructure, have contributed to increasing surgical volumes, particularly in emerging economies. Blood components such as plasma, red blood cells, and platelets are critical for managing hemorrhages and ensuring patient survival during surgeries and trauma care.This growing patient population is expected to substantially boost demand for blood preparation products, driving market growth in the coming years.
01 Risk of Contamination and Transmission of Infections One of the major restraints in the global blood preparation market is the persistent risk of contamination and transmission of infections during blood collection, storage, and transfusion. Despite rigorous screening procedures, there remains a possibility of transmitting diseases like HIV, hepatitis B and C, and syphilis. This risk is particularly high in regions with inadequate healthcare infrastructure and limited access to advanced screening technologies.Moreover, improper handling and storage of blood products can lead to bacterial contamination, compromising patient safety. These challenges not only deter patients and healthcare providers from trusting blood products but also result in increased regulatory scrutiny and operational costs for manufacturers and blood banks.
01 Increasing Research on Rare Blood Diseases and Their Treatments. The increasing focus on rare blood diseases presents a significant growth opportunity for the global blood preparation market. Rare blood disorders, like paroxysmal nocturnal hemoglobinuria (PNH), sickle cell anemia, and hemophilia, are receiving heightened attention from pharmaceutical companies and research institutions. This is driven by advancements in genomics and biotechnology, which are enabling the development of targeted and more effective treatments.The pursuit of innovative therapies for such conditions is expected to expand treatment options and foster investment in blood preparation technologies.
February 2026 Macopharma expanded its blood preparation portfolio with next-generation blood bag systems and automated processing technologies. The launch strengthens its offerings for blood centers, hospitals, and transfusion services.
October 2025 Fresenius Kabi introduced enhanced blood collection and processing solutions featuring improved automation and quality control capabilities. The innovations help blood banks optimize component preparation and storage efficiency.
August 2025 Haemonetics expanded its blood management solutions following the integration of Attune Medical, strengthening its hospital blood management and patient care portfolio. The expansion supports advanced blood preparation and temperature management technologies.
May 2025 Terumo Blood and Cell Technologies expanded its automated blood processing portfolio with new software enhancements for blood component preparation systems. The updates improve workflow efficiency, traceability, and blood product quality in transfusion centers.